Applied Filters
Has the public got the taste for free medicine?
The COVID-19 pandemic has seen the fundamental principles of the IP system called into question. How can we go on as before?
AG advises CJEU to uphold €94 million pay-for-delay fine
The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
English court gives Mylan green-light to sell generic insomnia drug
In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.
Teva to face inhaler infringement allegations in UK court
Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
FDA warns of ‘grave’ knock-on effects from Eagle decision
The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
FDA approves Hikma’s Vascepa generic
London-based Hikma Pharmaceuticals has won approval to launch the first generic version of Vascepa, after having key Amarin patents for the heart drug invalidated.
Gilead agrees 127-country remdesivir licence with generic makers
Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
US judge dismisses attorney’s ‘opportunistic’ whistleblower suit
A Californian judge has thrown out an attorney’s whistleblower lawsuit alleging Bausch Health Companies fraudulently obtained a patent for its ulcerative colitis drug Apriso.
Fed Circuit affirms generic maker’s win over Eagle
The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Bausch Health resolves IBS patent litigation
Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
